Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 6, 2005Journal of Clinical OncologyOpen Access

Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study

View Full Paper
Ask AI
Bookmark
Share

Authors

FHFred R. HirschStatens Serum InstitutMVMarileila Varella‐GarciaUniversity of Colorado Anschutz Medical CampusJMJason McCoyUniversity of Illinois Chicago

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hirsch et al. (2005) studied this question.

synapsesocial.com/papers/6a80cc9b9eee955937645dcahttps://doi.org/10.1200/jco.2005.01.2823
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tyrosine Kinase Inhibition: An Approach to Drug Development1995 · 1,658 citations
  2. 2A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial2004 · 263 citations
  3. 3Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib2004 · 11,591 citations
  4. 4EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib2004 · 4,368 citations